List of Excipients in Branded Drug LIOTHYRONINE SODIUM

Generic Drugs Containing LIOTHYRONINE SODIUM

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	liothyronine sodium	0093-2179	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	liothyronine sodium	0093-2179	EDETATE DISODIUM
Teva Pharmaceuticals USA Inc	liothyronine sodium	0093-2179	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in LIOTHYRONINE SODIUM?

# Of NDCs	Excipient
1	ALCOHOL
1	AMMONIA
1	ANHYDROUS CITRIC ACID

Liothyronine Sodium Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Liothyronine sodium is an old, genericized thyroid hormone with limited composition-of-matter value but continuing commercial demand. The strongest opportunities are differentiated dosage forms, dose-uniformity technologies, pediatric and geriatric delivery systems, preservative-controlled liquids, and products that improve adherence without changing the active ingredient. Conventional immediate-release tablets face low patent barriers and intense generic competition.

What is the commercial status of liothyronine sodium?

Liothyronine sodium is the sodium salt of triiodothyronine, or T3, the active thyroid hormone. It is marketed in oral tablet products, including Cytomel and generic equivalents, generally in 5 mcg, 25 mcg, and 50 mcg strengths. The product is used primarily for hypothyroidism and selected thyroid-suppression indications under physician supervision.[1]

Attribute	Commercial assessment
Active ingredient	Liothyronine sodium
Pharmacology	Synthetic T3 thyroid hormone
Principal route	Oral
Common strengths	5 mcg, 25 mcg, 50 mcg
Reference product	Cytomel
Regulatory pathway	NDA reference product; ANDA generic pathway
Small-molecule exclusivity	Expired
Biosimilar exposure	Not applicable
Current patent barrier	Low for conventional tablets
Main product risk	Narrow dose margin, peak-related adverse effects, dose-uniformity requirements
Main opportunity	Improved delivery, stability, dose flexibility, and patient usability

Liothyronine has a faster onset and shorter effective half-life than levothyroxine. That pharmacokinetic profile creates demand for predictable release and may support controlled-release or combination-product development, although those products would face greater clinical and regulatory requirements than conventional tablets.[2]

What excipients are used in liothyronine sodium tablets?

The excipient system varies by manufacturer and dosage strength. Public labels for liothyronine products identify conventional tablet excipients such as fillers, binders, disintegrants, lubricants, and coloring agents. The exact composition should be confirmed against the current package insert and DailyMed record for each product.[1,3]

Functional excipient categories

Excipient function	Candidate materials	Relevance to liothyronine
Diluent	Lactose, microcrystalline cellulose, calcium sulfate, mannitol	Supports tablet mass when the drug load is measured in micrograms
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet integrity
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Controls tablet breakup and dissolution
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces manufacturing friction
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Sweetener	Sucrose, mannitol, sucralose	Supports pediatric, chewable, or orally disintegrating formats
Suspending agent	Hydroxypropyl methylcellulose, xanthan gum, microcrystalline cellulose systems	Supports liquid formulations
Preservative	Sodium benzoate, potassium sorbate, parabens	May be required for multidose aqueous products
Buffer	Citrate, phosphate, acetate systems	Controls pH and chemical stability
Antioxidant or chelator	Product-specific antioxidant and metal-control systems	May reduce degradation risk in liquid products
Film coat	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Protects tablets and improves identification

The central formulation challenge is not simply tablet hardness. It is achieving uniform distribution of a microgram-level active ingredient across the blend and maintaining consistent dissolution across strengths. Excipient selection therefore has direct implications for content uniformity, assay variability, and dose accuracy.

How should an excipient strategy address liothyronine’s low dose?

A robust strategy should prioritize geometric dilution, controlled granulation, low-segregation powders, and validated sampling plans. A 5 mcg tablet contains a very small quantity of active relative to the total tablet mass. Conventional direct blending can create potency variation if particle size, density, or electrostatic behavior differs between liothyronine sodium and the excipient system.

Preferred development approach

1. Use a preblend or premix to distribute liothyronine sodium before final blending.
2. Match active and excipient particle-size distributions where practical.
3. Limit segregation during transfer, compression, and packaging.
4. Evaluate dry granulation or wet granulation if direct compression does not provide reliable uniformity.
5. Control lubricant concentration and blending time because excessive lubrication can slow dissolution.
6. Test blend uniformity at multiple process locations.
7. Establish strength-specific dissolution specifications rather than assuming dose-proportional behavior.
8. Use packaging with low moisture transmission and light protection when stability data support those controls.

The most defensible formulation patent position would usually be based on a demonstrated technical effect, such as improved content uniformity, reduced degradation, faster disintegration, or improved stability in a multidose liquid. A claim directed only to the use of a conventional filler or lubricant would have limited durability.

What formulations are protected or commercially available for liothyronine sodium?

Conventional immediate-release tablets are the established product category. Their basic formulation architecture is old and generally available to generic manufacturers. The commercial white space is concentrated in differentiated delivery systems.

Immediate-release tablets

These remain the lowest-risk regulatory route. Opportunities include:

• Improved scoreability for precise dose splitting.
• Smaller tablets for 5 mcg and pediatric dosing.
• Low-allergen or excipient-minimized formulations.
• Color-coded strength identification.
• Packaging that reduces moisture and light exposure.
• Better content uniformity at the lowest strength.

A generic tablet must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. Because liothyronine is administered at very low doses, manufacturing controls can be commercially important even when the formulation itself is not patentable.[4]

Oral liquid

An oral liquid could address patients who cannot swallow tablets, pediatric dosing, and flexible titration. It also creates a more substantial excipient development program.

Key formulation issues include:

• Chemical stability in water-containing systems.
• Adsorption to container closures or dosing devices.
• Uniform suspension or true-solution behavior.
• Preservative effectiveness.
• Dose recovery from oral syringes.
• Compatibility with common feeding systems.
• In-use stability after opening.
• Protection from light and temperature variation.

A liquid can support a 505(b)(2) strategy if it offers a materially different dosage form or clinical-use profile, but it would not automatically receive broad market protection. The sponsor would need a regulatory and clinical justification for the new presentation.[5]

Orally disintegrating and chewable tablets

Orally disintegrating tablets could address dysphagia and adherence. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking systems are potential excipient tools. The principal risks are poor taste, friability, moisture sensitivity, and dose loss during handling.

Because liothyronine is potent at microgram quantities, a taste-masked product must avoid excessive excipient mass while preserving dose uniformity. A strong commercial product would combine rapid disintegration with a stable unit-dose package.

Modified-release formulations

Modified-release liothyronine is the most technically differentiated opportunity. The goal would be to reduce peak exposure and produce a more physiologic exposure profile. Candidate technologies include hydrophilic matrix tablets, multiparticulates, coated pellets, osmotic systems, and lipid-based delivery.

The regulatory burden is high. Developers would need to establish a clinically meaningful pharmacokinetic and pharmacodynamic profile, account for endogenous thyroid hormone concentrations, and demonstrate that the formulation does not produce clinically important T3 excursions. A modified-release product could support method-of-use, formulation, and potentially regulatory exclusivity, but it would not be a straightforward generic substitution.

When does liothyronine sodium lose exclusivity?

The principal composition-of-matter and basic product exclusivity periods for liothyronine sodium expired decades ago. Cytomel and related products are established products, not new molecular entities with current NCE exclusivity.[1,4]

Exclusivity or barrier	Status
New chemical entity exclusivity	Expired
Original composition patents	Expired
Conventional tablet patent barrier	Low
Generic ANDA pathway	Available
Pediatric exclusivity	No general current barrier identified
Orphan exclusivity	Not a general feature of liothyronine tablets
Biosimilar exclusivity	Not applicable
New formulation exclusivity	Depends on the approved product and regulatory pathway

The commercial barrier is therefore manufacturing quality, regulatory execution, physician acceptance, distribution, and supply reliability rather than basic active-ingredient patent protection.

What is the Orange Book status of liothyronine sodium?

The FDA Orange Book identifies approved drug products and relevant patent or exclusivity information. Conventional liothyronine sodium tablets are listed through approved NDA and ANDA products, with Cytomel as the reference product.[4]

The practical Orange Book implications are:

• Generic applicants can pursue ANDA approval for pharmaceutically equivalent tablet strengths.
• Any current patent certification must be assessed against the specific reference listing and Orange Book edition.
• A Paragraph IV certification is relevant only if an applicant challenges a listed patent.
• Expired historical patents do not prevent generic approval.
• Formulation patents for a new liquid, modified-release system, or device-linked product may not block ordinary immediate-release tablets unless properly listed and relevant to the proposed product.

A current filing or launch analysis should use the FDA Orange Book and the relevant patent listing date because listed patents and product records can change.[4]

Which companies are challenging or competing with Cytomel?

Competition is primarily from generic manufacturers rather than biosimilar developers. Public product records identify multiple approved liothyronine sodium tablet suppliers over time, while Cytomel remains the branded reference product.[3,4]

Competitive groups

Competitive group	Product strategy	Competitive advantage
Cytomel	Branded immediate-release tablets	Brand recognition and reference-product status
Generic tablet manufacturers	5 mcg, 25 mcg, 50 mcg tablets	Lower price and payer substitution
Specialty pharmacies	Compounded capsules, liquids, or customized doses	Flexible dosing, but variable commercial and regulatory positioning
Specialty formulation developers	Modified-release, liquid, ODT, or combination products	Potential differentiation and pricing power
API suppliers	Liothyronine sodium active pharmaceutical ingredient	Supply reliability and cost control

Compounded products are not equivalent to FDA-approved commercial products. Their quality, stability, and dose uniformity depend on the compounding operation and formulation process. That distinction creates an opportunity for an FDA-approved liquid or flexible-dose product with validated stability and dosing accuracy.

What generic entry risks exist for liothyronine sodium?

Generic entry risk is high for conventional tablets because the active ingredient is old, the reference product is established, and the dosage forms are technically familiar. The principal risks to an incumbent are price erosion, pharmacy substitution, channel inventory shifts, and supply-driven switching.

Paragraph IV risk

Paragraph IV litigation is likely to be limited for standard liothyronine tablets because the core patent estate is old. A new branded formulation could create a different risk profile if it relies on:

• A listed formulation patent.
• A method-of-use patent.
• A delivery-device patent.
• A controlled-release technology.
• A stability or packaging patent with product relevance.

For an established immediate-release tablet, a Paragraph IV challenge would have limited strategic value unless a currently listed patent remains enforceable and commercially meaningful.

What method-of-use patents could protect liothyronine products?

Method-of-use patents may target patient segments or treatment regimens rather than the molecule itself. Potential categories include:

• Specific hypothyroidism populations.
• Combination treatment with levothyroxine.
• Carefully defined titration schedules.
• Use in patients with particular absorption or conversion characteristics.
• Pediatric or geriatric administration methods.
• Controlled-release dosing regimens.

These claims face significant validity and enablement risks because liothyronine’s therapeutic use is well established. A method-of-use patent is more commercially credible when it is tied to a distinct dosage form, measurable patient-selection criterion, or clinically demonstrated dosing benefit.

How strong is the liothyronine sodium patent estate?

The patent estate is weak for conventional tablets and potentially moderate for a genuinely differentiated delivery system.

Patent category	Strength for conventional tablet	Strength for new product
Composition of matter	Very low	Not relevant
Basic tablet formulation	Low	Low to moderate if a technical effect is proven
Low-dose uniformity process	Low to moderate	Moderate if supported by robust data
Oral liquid formulation	Low for old disclosures	Moderate if stability and dosing advantages are novel
Modified release	Low for generic tablets	Moderate to strong if clinically differentiated
Method of use	Low to moderate	Moderate in a narrow, evidence-based population
Packaging and device	Low	Moderate for an integrated product

The most valuable intellectual property would combine formulation claims, manufacturing claims, packaging claims, and clinically specific use claims. A single broad excipient patent would be vulnerable to design-around and obviousness challenges.

What licensing deals and manufacturing barriers affect the market?

Publicly visible commercial activity in liothyronine is primarily product supply and generic competition rather than major active-ingredient licensing transactions. The molecule is widely known, and the main licensing value would arise from a differentiated formulation, proprietary delivery platform, or regional distribution arrangement.

Manufacturing barriers include:

• Reliable sourcing of high-quality liothyronine sodium API.
• Microgram-scale content uniformity.
• Cross-contamination control for potent thyroid hormone.
• Strength-specific compression and assay validation.
• Stability under humidity and light exposure.
• Container-closure compatibility.
• Control of tablet splitting and dose recovery.
• Consistent supply across multiple strengths.

API and finished-dose supply interruption can create commercial value even without patent protection. A manufacturer with validated low-dose manufacturing, redundant API sourcing, and strong regulatory compliance can compete effectively in a commoditized market.

What revenue exposure and commercial opportunities exist?

Standalone liothyronine revenue is difficult to isolate because public companies often report it within broader generic or endocrine portfolios. The product is unlikely to support a large premium franchise as an ordinary tablet, but it can support focused opportunities in underserved dosage forms.

Highest-priority opportunities

1. FDA-approved oral liquid for pediatric and dysphagia populations.
2. Unit-dose or multidose product with validated dose recovery.
3. Orally disintegrating tablet with low excipient burden.
4. Modified-release product targeting reduced T3 peak exposure.
5. Low-allergen tablet with a simplified excipient profile.
6. Contract manufacturing for specialty pharmacies and generic suppliers.
7. Regional licensing of differentiated formulations.
8. Combination products involving liothyronine and levothyroxine, subject to clinical justification.

The strongest near-term commercial case is a stable, accurately dosed liquid or flexible-dose tablet. The strongest long-term patent case is a clinically validated modified-release product, but its development cost and regulatory risk are materially higher.

What FDA regulatory issues apply to new liothyronine formulations?

A conventional generic tablet would generally follow the ANDA pathway. A new dosage form, strength, route, delivery technology, or combination may require an NDA or 505(b)(2) application, depending on the product design and FDA determination.[5]

Key regulatory issues include:

• Demonstrating content uniformity at microgram strengths.
• Establishing bioequivalence or a scientifically justified alternative.
• Controlling endogenous T3 and T4 in pharmacokinetic studies.
• Characterizing peak concentration and exposure variability.
• Demonstrating multidose liquid homogeneity.
• Providing extractables and leachables data.
• Establishing in-use stability.
• Validating dose delivery through oral syringes or other devices.
• Supporting any clinical claims for modified release or combination therapy.

Key Takeaways

• Liothyronine sodium has no meaningful composition-of-matter exclusivity remaining.
• Conventional tablets face high generic entry and low pricing power.
• Excipient selection is strategically important because the active dose is measured in micrograms.
• Blend uniformity, segregation control, stability, and dose recovery are the main formulation issues.
• Oral liquids and orally disintegrating tablets offer practical commercial differentiation.
• Modified-release liothyronine offers the strongest potential patent position but carries the highest clinical and regulatory risk.
• Biosimilar competition does not apply because liothyronine sodium is a synthetic small molecule.
• The most defensible IP strategy combines formulation, manufacturing, packaging, and narrow method-of-use claims.
• Supply reliability and quality execution may create more value than conventional product patents.

FAQs

Can liothyronine sodium be formulated without lactose?

Yes. Lactose-free formulations can use microcrystalline cellulose, mannitol, calcium sulfate, starches, or other suitable fillers. The replacement must be evaluated for blend uniformity, compression, dissolution, stability, and patient tolerability.

Is liothyronine sodium suitable for an oral suspension?

It can be developed as an oral solution or suspension, but the product must demonstrate uniform dosing throughout shelf life and in-use storage. Suspension products require close control of settling, redispersion, particle size, preservative performance, and oral-syringe dose recovery.

Can a liothyronine sodium product receive new patent protection?

Yes, but protection would normally target a novel formulation, delivery system, manufacturing method, packaging configuration, or narrowly defined treatment method rather than the active molecule itself. The claims require a credible technical or clinical distinction from prior art.

Are compounded liothyronine capsules a substitute for an FDA-approved product?

They are not automatically equivalent. Compounded products may provide customized strengths or dosage forms, but their quality controls, stability data, and dose uniformity depend on the compounding operation. FDA-approved products have a different evidentiary and manufacturing framework.

What is the most attractive excipient-led product concept?

A unit-dose or multidose oral liquid with validated homogeneity, low adsorption, reliable preservative performance, and accurate syringe delivery is among the most practical opportunities. It addresses dosing flexibility and administration barriers while creating a stronger formulation and regulatory position than another standard tablet.

References

1. Pfizer. (2023). Cytomel (liothyronine sodium) tablets: Prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov
2. Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., & Sawka, A. M. (2014). Guidelines for the treatment of hypothyroidism. Thyroid, 24(12), 1670-1751. https://doi.org/10.1089/thy.2014.0028
3. National Library of Medicine. (2024). DailyMed: Liothyronine sodium drug labels. https://dailymed.nlm.nih.gov
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
5. U.S. Food and Drug Administration. (2023). 505(b)(2) applications. https://www.fda.gov/drugs/types-applications/505b2-application-relies-existing-drug-approval for safety or effectiveness-supporting data